| Methods |
Randomised
Controlled
Trial
Double‐blind
Blinded assessor
Placebo‐ controlled
Multicentre (n=4) |
| Participants |
Country: Canada and USA
Mean age: NR
% Female: NR
Mean disease duration: NR
Duration: 8 wk
Number randomised:
(HA 19, PL 20)
Inclusion:
NR
Exclusion:
NR
Baseline values:
NR |
| Interventions |
Replasyn/
Hyalgan (20 mg)
3 weekly injections
Placebo (not specified) |
| Outcomes |
Knee pain when walking (100 mm VAS),
Range of motion,
WOMAC OA functional Index,
Pt and MD overall global |
| Notes |
Jadad's:4/5
No baseline differences between groups.
Supported by a grant from Bioniche Pharm‐
aceuticals, London, ON, Canada. |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment (selection bias) |
Unclear risk |
B ‐ Unclear |
